Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pain 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Carcinoma in Situ 1Breast Diseases 1Agnosia 1

Interventions

valrubicin 3dodecyl maltoside 3Mitomycin 3Gemcitabine 3durvalumab 2Magnetic Resonance Imaging 2Electrocardiography 2Diphenhydramine 2Cystoscopy 2Biopsy 2Acetaminophen 2toripalimab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1enfortumab vedotin 1cemiplimab 1apaziquone 1aldesleukin 1advexin 1Tomography, X-Ray Computed 1Surveys and Questionnaires 1Standard of Care 1Respiratory Function Tests 1Proflavine 1Prochlorperazine 1Positron-Emission Tomography 1Physical Examination 1Ondansetron 1Oncolytic Virotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma in Situ × Codeine × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡